Adjuvant Multiagent Chemotherapy Regimens Associated with OS Benefit Following Resection of Localised Pancreatic Adenocarcinoma Following Preoperative (m)FOLFIRINOX By Ogkologos - March 11, 2025 549 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a retrospective cohort study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Revumenib for Relapsed or Refractory Acute Myeloid Leukaemia with a Susceptible NPM1 Mutation Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active Brain Metastases of Breast Cancer and NSCLC EMA Recommends Extension of Indications for Sugemalimab MOST POPULAR How Joining a Clinical Trial Helped Me Find Hope While Living... December 5, 2023 Misdiagnosis: Her Doctor Dismissed Her Concerns For Months Then Told Her... June 2, 2020 A Safer, Better Treatment Option for Some Younger Women with Breast... January 11, 2023 New on NCI’s Websites for December 2022 December 27, 2022 Load more HOT NEWS German Shepherds Detect Fast-Growing Form Of Breast Cancer And Save Their... Foodie Fridays: Farmer’s Market Finds Breast Cancer Survivor Says Mistletoe Injections Have Kept Her Cancer-Free For... Insulin Resistance May Contribute to Poorer Breast Cancer Outcomes, Study Says
